Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer

  Millennium: The Takeda Oncology Company and the WIN Consortium Become
  Partners in the Fight Against Cancer

Business Wire

CAMBRIDGE, Mass. -- March 29, 2013

Millennium: The Takeda Oncology Company and the Worldwide Innovative Network
(WIN) in personalized cancer medicine Consortium today announced the formation
of a new partnership focused on bringing the latest advances in personalized
cancer treatments to patients. The WIN Consortium is a global network of
leading academic, industry, and patient advocacy organizations working to make
personalized cancer care a reality for patients worldwide. It was founded on
the recognition that greater success can be achieved through collaboration
than any organization can achieve alone.

“Millennium has a long-standing commitment to advancing personalized medicine
in oncology,” said Jesus Gomez Navarro, M.D., Vice President, Clinical
Research at Millennium and delegate to the WIN Consortium. “WIN’s global
network of cancer centers and industry partners provides Millennium with
unique opportunities to build successful industry-leading partnerships that
accelerate the development of new therapies and advance our aspiration to cure
cancer.”

“WIN’s achievements are built by the collaborative efforts of its members,”
said John Mendelsohn, M.D., Director, Khalifa Institute for Personalized
Cancer Therapy and Past-President, The University of Texas MD Anderson Cancer
Center, and Chairman of the WIN Consortium. “Millennium’s focus on partnership
development and the development of novel oncology therapeutics for a global
population strongly align with WIN’s mission and goals. This partnership
increases the potential of the Consortium and will enhance its future
achievements. We are thrilled that Millennium has become a premier member of
WIN.”

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome
inhibitor, and has a robust clinical development pipeline of product
candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda
Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development
and commercialization activities are focused in oncology. Additional
information about Millennium is available through its website,
www.millennium.com.

About the WIN Consortium

Initiated in 2010 by the University of Texas MD Anderson Cancer Center (USA)
and the Institut Gustave Roussy (France), the WIN Consortium is a global
network of 28 leading organizations from the academic, pharmaceutical,
biotechnology, healthcare IT, and patient advocacy sectors working to
accelerate the pace and reduce the cost of translating novel cancer treatments
to the bedside by developing and applying, through worldwide clinical trials
and research projects, the most promising advances in genomic-based cancer
research. WIN is a non-governmental, not-for-profit organization headquartered
in Paris.

For further information, please visit www.winconsortium.org.

Contact:

Millennium:
Manisha Pai, +1 617 551 7877
Manisha.pai@mpi.com
or
WIN:
Catherine Bresson, +33 1 42 11 40 20
Catherine.bresson@winconsortium.org